BRISTOL MYERS SQUIBB CO (BMY) earnings date, results and what the price requires
NYSE · SEC CIK 0000014272 · SEC filings checked Oct 16, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 30, 2026 | $12.97B | $3.32B | $1.62 | Filing |
| Mar 31, 2026 | Apr 30, 2026 | $11.49B | $2.68B | $1.31 | Filing |
| Dec 31, 2025 | Feb 5, 2026 | $12.50B | $1.09B | $0.54 | Filing |
| Sep 30, 2025 | Oct 30, 2025 | $12.22B | $2.20B | $1.08 | Filing |
| Jun 30, 2025 | Jul 31, 2025 | $12.27B | $1.31B | $0.64 | Filing |
| Mar 31, 2025 | Apr 24, 2025 | $11.20B | $2.46B | $1.20 | Filing |
| Dec 31, 2024 | Feb 6, 2025 | $12.34B | $72.0M | $0.05 | Filing |
| Sep 30, 2024 | Oct 31, 2024 | $11.89B | $1.21B | $0.60 | Filing |
What would BRISTOL MYERS SQUIBB CO have to report for its valuation to change?
At $60.57, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 2.6% a year, to $5.18. On that path the next quarter needs diluted EPS near $1.11, against $1.08 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 2.6% | 2.6% |
| EPS needed in final year | $5.18 | $5.18 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. BMY goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.